Today's Food and Drug Administration (FDA) approval of the first CAR T-cell therapy for mantle cell lymphoma (MCL) represents a key advance for patients with relapsed or treatment-resistant forms of the disease, say Dana-Farber ...
Jul 24, 2020
0
3
A team of researchers investigating how a certain type of drugs can kill cells has discovered that these drugs can do more harm than good when used in combination with other cancer treatments.
Jul 24, 2020
0
2
CAR-T cell therapy, which attacks cancer cells using a person's reprogrammed immune cells, has been used to treat Hodgkin lymphoma with remarkable success for the first time, according to the results of an early phase clinical ...
Jul 23, 2020
0
3
A general problem encountered in cancer therapy is that many patients develop resistance to a drug over the course of treatment. In the case of the blood cancer anaplastic large cell lymphoma (ALCL), an international team ...
Jul 15, 2020
0
0
A research team led by Hong Kong Baptist University (HKBU) has developed a novel anti-Epstein-Barr virus (EBV) drug that can selectively disrupt a viral protein produced by EBV, leading to the shrinkage of tumors caused by ...
May 11, 2020
0
8
Creating new blood vessels, a process called angiogenesis, for tumors in lymph nodes is different than for tumors in other parts of the body, such as the colon or lung, a team from the Max Delbrueck Center for Molecular Medicine ...
Apr 7, 2020
0
32
A one-year follow-up study led by The University of Texas MD Anderson Cancer Center revealed a majority of patients with mantle cell lymphoma resistant to prior therapies may benefit from treatment with CD19-targeting chimeric ...
Apr 1, 2020
0
13
The National Institute for Health and Care Excellence (NICE) has not recommended a new combination therapy for adults with an aggressive type of non-Hodgkin lymphoma on the NHS in England.
Mar 12, 2020
0
1
Researchers from the University of Tsukuba have shown by in vivo experimentation on a mouse model that angioimmunoblastic T-cell lymphoma is highly dependent on T-cell receptor signaling. Further trials also suggest that ...
Feb 28, 2020
0
3
Walter and Eliza Hall Institute researchers have revealed a new vulnerability in lymphomas that are driven by one of the most common cancer-causing changes in cells.
Feb 20, 2020
0
8
